As a pediatric oncologist, Dr Eveline Barbieri’s research efforts have been focused on the development of novel targeted therapies for high-risk neuroblastoma.  Her research goals and interests lie at the intersection between the study of molecular mechanisms driving neuroblastoma oncogenesis, tumor metabolism, and translational oncology.  Following training in the Shohet lab at Baylor College of Medicine, she developed xenograft models of neuroblastoma and effective combination therapies for high-risk disease in the early stage of her career.  Since then, her laboratory has established a definitive role of epigenetic regulator CHAF1A in blocking neural crest differentiation and promoting neuroblastoma oncogenesis by rewiring tumor metabolism.  Her laboratory has also uncovered novel MYCN-specific and time-specific metabolic dependencies and pathways that serve as targets for neuroblastoma treatment, while also characterizing the metabolic landscape of neuroblastoma primary tumors and defining MYCN amplification as a major driver of distinct intrinsic metabolic adaptations within the tumor microenvironment.  Dr Barbieri will be presenting her seminar entitled “MYCN-driven Neuroblastoma: Metabolism and Therapeutic Interventions.”